Suven Life Sciences Limited (BOM:530239)

Market Cap	87.17B +88.4%
Revenue (ttm)	88.14M +17.3%
Net Income	-3.52B
EPS	-14.74
Shares Out	282.56M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	43,738
Open	321.65
Previous Close	320.00
Day's Range	300.85 - 321.65
52-Week Range	124.35 - 402.90
Beta	0.84
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About Suven Life Sciences

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally. It engages in the development of Masupirdine (SUVN-502), a 5-HT6 receptor antagonist for the treatment of cognitive and neuropsychiatric symptoms of Alzheimer’s disease; and Samelisant (SUVN-G3031), a histamine H3 receptor inverse agonist/antagonist for the treatment of narcolepsy with or without cataplexy and idiopathi...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1989
• Employees: 142
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530239

Financial Performance

In fiscal year 2026, Suven Life Sciences's revenue was 71.15 million, an increase of 6.89% compared to the previous year's 66.56 million. Losses were -2.76 billion, 71.9% more than in 2025.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 3, 2026

Data Sources Report a data error